Iambic Therapeutics: $500M valuation, IPO Readiness 55, Series B. AI-driven drug discovery company using machine learning to design small molecule drugs faster. Track live on The IPO Stack.
AI-driven drug discovery company using machine learning to design small molecule drugs faster.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Iambic Therapeutics IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Iambic Therapeutics has not publicly announced IPO plans. Track TechStackIPO for the latest signals and subscribe to The IPO Stack for weekly updates.
Iambic Therapeutics is valued at $500M as of October 2022. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Accredited investors can access Iambic Therapeutics shares through secondary market platforms, pre-IPO investment funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace tracks available access options. Note: pre-IPO investments carry higher risk and limited liquidity compared to public market investing.
Iambic Therapeutics scores 55/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Iambic Therapeutics has raised $250M in total venture capital and private equity funding, with backing from Andreessen Horowitz Bio, 8VC, Polaris Partners.
Iambic Therapeutics's notable investors include Andreessen Horowitz Bio, 8VC, Polaris Partners. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Iambic Therapeutics is a Biotechnology company. AI-driven drug discovery company using machine learning to design small molecule drugs faster.